Genovis AB (publ.) (STO:GENO)

Market Cap	1.35B
Revenue (ttm)	117.66M
Net Income (ttm)	21.18M
Shares Out	66.06M
EPS (ttm)	0.32
PE Ratio	63.04
Forward PE	44.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,637
Average Volume	162,615
Open	20.70
Previous Close	20.45
Day's Range	19.90 - 20.85
52-Week Range	17.10 - 30.45
Beta	2.12
RSI	45.15
Earnings Date	Nov 7, 2025

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 32
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2024, Genovis AB (publ.)'s revenue was 131.32 million, a decrease of -17.44% compared to the previous year's 159.07 million. Earnings were 32.92 million, a decrease of -46.48%.